Toll-like receptor 7 (TLR7) agonist. Induces upregulation of IL-6, IL-12, IFN-γ
and iNOS expression in mouse bone marrow-derived macrophages (BMMs). Inhibits RANKL-induced osteoclast differentiation in mouse BMMs and human peripheral blood monocytes. Also promotes the differentiation of MDSCs into macrophages and dendritic cells. Proinflammatory and antiviral.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Imiquimod and resiquimod as novel immunomodulators.
Dockrell and Kinghorn
R848, a toll-like receptor 7 agonist, inhibits osteoclast differentiation but not survival or bone-resorbing function of mature osteoclasts.
Miyamoto et al.
Modulation of TH1 and Th2 cytokine production with the immune response modifiers, R-848 and imiquimod.
Wagner et al.
Cell Immunol., 1999;191:10
Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells.
Lee et al.